AGEAS

HEALTH CHECK

16/05/24 -"As we have consistently argued over the last 3 years, Health stocks (ex Pharma) are long on growth promises and short on delivery. The gap stems from the fact that delivery hinges on buying the next ..."

PDF page sample
Pages
45
Language
English
Published on
16/05/24
Download
You may also be interested by these reports :
03/06/26
Legal & General’s (REDUCE; UK) strong share price correlation with the sector average does little to reveal the profound changes the company has ...
02/06/26
We have revised our assumptions and adopted a more prudent scenario for the reinsurance sector following the release of 1Q26 results and news flow ...
01/06/26
UNIQA delivered a strong 1Q26 performance across all three divisions, with the main positive surprise coming from Property & Casualty, where volume ...
19/05/26
We are upgrading our FY26 EPS estimate following Swiss Re’s 1Q26 results, which significantly exceeded expectations. Group net income came in at ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO